Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Bohl

Neurological Surgery Charlotte, NC Medical Doctor

NPI 1073952974 CMS profile 365530

225 Baldwin Ave, Charlotte, NC 28204

Open in the dashboard

General payments

$120,204

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Bohl of Charlotte, NC is reported in the CMS Open Payments database as having received $120,204 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50,121 43
2024 General $18,453 31
2023 General $17,773 37
2022 General $4,075 31
2021 General $8,610 17
2020 General $12,775 31
2019 General $8,397 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Bohl
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Michael Bohl were reported at $50,121. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Michael Bohl Neurological Surgery median Middle half National median
2019 $8,397 $582 $138–$3,006 $163
2020 $12,775 $294 $76–$2,174 $114
2021 $8,610 $387 $105–$2,432 $132
2022 $4,075 $542 $139–$2,989 $149
2023 $17,773 $534 $145–$2,697 $160
2024 $18,453 $574 $155–$3,046 $164
2025 $50,121 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $77,836 52 payments
  2. Stryker Corporation $8,263 22 payments
  3. MiRus, LLC $8,012 4 payments
  4. DePuy Synthes Products, Inc. $5,155 2 payments
  5. Bioventus LLC $4,396 3 payments
  6. NuVasive, Inc. $3,744 36 payments
  7. Globus Medical, Inc. $3,512 19 payments
  8. DePuy Synthes Sales Inc. $3,274 55 payments
  9. Biocomposites Inc $1,500 1 payment
  10. Spine Wave, Inc. $1,427 5 payments
  11. Other $3,087 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $86,138 18 payments
  2. Travel and Lodging $14,558 46 payments
  3. Food and Beverage $9,147 158 payments
  4. Education $5,737 4 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,374 3 payments
  6. Entertainment $250 3 payments
Products named General payments · program years 2019–2025
  1. CYGNUS Anterior Cervical Plate $8,012 4 payments
  2. EUROPA Pedicle Screw System $8,012 4 payments
  3. GENERAL K2M PRODUCT DISCUSSION $5,637 3 payments
  4. BONESCALPEL & SONICONE (O.R.) $4,396 3 payments
  5. EXPEDIUM Spine $2,301 16 payments
  6. RELINE $1,518 11 payments
  7. EXPEDIUM Spine $1,507 27 payments
  8. Stimulan $1,500 1 payment
  9. RISE $1,486 2 payments
  10. Velys $1,396 7 payments
  11. Other $15,668 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

173

Median for Neurosurgery: 83

Drug cost

$2,187

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 68 $1,059
Gabapentin Generic 57 $835
Tizanidine Hcl Generic 19 $154
Cyclobenzaprine Hcl Generic 14 $131
Meloxicam Generic 15 $8

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$446,216

Medicare's payments for the services billed

Medicare patients

249

Average age 73

Services billed

1,651

143 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Ischemic heart disease 34%
Chronic kidney disease 32%
Diabetes 31%
Osteoporosis 27%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record